



Contact:

Robert Gottlieb
RMG Associates, LLC
857-891-9091
Robertmg52@gmail.com

Cellanyx takes first place at the Medstartr pitch contest during San Diego Startup Week, 2017.

Beverly, MA, July 21, 2017 – Cellanyx’s live cell biomarker test data demonstrating the potential to stratify prostate cancer risk as well as its phenotypic platform were presented at the Medstartr Pitch Fest at San Diego Startup Week, 2017, and Cellanyx took first place in the [Bio/Med category](#). As the San Diego region’s largest startup focused event, Startup Week brings together entrepreneurs to share progress, exchange resources, and celebrate the thriving innovation community.

About Cellanyx

Cellanyx is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making. The company’s unique ‘biopsy-on-a-chip’ methodology provides quantitative, actionable assessment of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor aggressiveness and metastatic potential. Cellanyx has demonstrated clinical proof-of-concept with its lead product in development, a diagnostic to improve risk stratification in men with prostate cancer. Learn more at www.cellanyx.com.

Contact:

Ashok Chander, CEO
ashok@cellanyx.com
978 473 7883

Robert Gottlieb, RMG Associates, LLC
Robertmg52@gmail.com
857 891 9091

###